Please wait while the formulary information is being retrieved.
Drug overview for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
Generic name: silver sulfadiazine/povidone-iodine/alginate dressing (SIL-ver SIL-fa-DYE-a-zeen)
Drug class: Topical Silver Sulfadiazine
Therapeutic class: Dermatological
Iodine, a nonmetallic element that forms salts with most other elements, Silver sulfadiazine is a synthetic anti-infective agent produced by the has germicidal activity. reaction of silver nitrate with sulfadiazine.
Iodine solution and tincture are used topically as antiseptics in the Silver sulfadiazine is used as an adjunct in the prevention and treatment management of minor, superficial skin wounds and have been used to of infection in second- and third-degree burns after resuscitative measures (including control of shock and pain, and correction of electrolyte disinfect the skin preoperatively. imbalance) have been instituted. Because infection may extend tissue destruction beyond the burned area and may destroy epithelial islands that could initiate healing, control of bacterial growth may prevent the conversion of deep, partial-thickness wounds to full thickness. Concomitant administration of appropriate systemic anti-infective agents may be necessary if infection is present or suspected.
Although silver sulfadiazine appears to be as effective as silver nitrate or mafenide, controlled studies comparing the effectiveness of silver sulfadiazine and other standard antibacterial burn treatments have not been published. Mafenide appears to penetrate the burn eschar better than does silver sulfadiazine and, therefore, may be more effective in minimizing the growth of bacteria. However, because of the softening action of silver sulfadiazine cream, removal of the eschar and preparation of the wound for grafting is apparently easier than after treatment with mafenide preparations.
Unlike mafenide, silver sulfadiazine is not a carbonic anhydrase inhibitor and, therefore, does not alter acid-base balance. Unlike silver nitrate solutions, silver sulfadiazine cream does not alter electrolyte balance and does not stain tissues or dressings.
Generic name: silver sulfadiazine/povidone-iodine/alginate dressing (SIL-ver SIL-fa-DYE-a-zeen)
Drug class: Topical Silver Sulfadiazine
Therapeutic class: Dermatological
Iodine, a nonmetallic element that forms salts with most other elements, Silver sulfadiazine is a synthetic anti-infective agent produced by the has germicidal activity. reaction of silver nitrate with sulfadiazine.
Iodine solution and tincture are used topically as antiseptics in the Silver sulfadiazine is used as an adjunct in the prevention and treatment management of minor, superficial skin wounds and have been used to of infection in second- and third-degree burns after resuscitative measures (including control of shock and pain, and correction of electrolyte disinfect the skin preoperatively. imbalance) have been instituted. Because infection may extend tissue destruction beyond the burned area and may destroy epithelial islands that could initiate healing, control of bacterial growth may prevent the conversion of deep, partial-thickness wounds to full thickness. Concomitant administration of appropriate systemic anti-infective agents may be necessary if infection is present or suspected.
Although silver sulfadiazine appears to be as effective as silver nitrate or mafenide, controlled studies comparing the effectiveness of silver sulfadiazine and other standard antibacterial burn treatments have not been published. Mafenide appears to penetrate the burn eschar better than does silver sulfadiazine and, therefore, may be more effective in minimizing the growth of bacteria. However, because of the softening action of silver sulfadiazine cream, removal of the eschar and preparation of the wound for grafting is apparently easier than after treatment with mafenide preparations.
Unlike mafenide, silver sulfadiazine is not a carbonic anhydrase inhibitor and, therefore, does not alter acid-base balance. Unlike silver nitrate solutions, silver sulfadiazine cream does not alter electrolyte balance and does not stain tissues or dressings.
DRUG IMAGES
No Image Available
The following indications for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
Iodine solution and tincture are applied topically to the affected areas as Silver sulfadiazine, as a 1% cream, is applied topically to cleansed, debrided, burned areas once or twice daily using a sterile-gloved hand. The necessary; to avoid irritation, surfaces to which the preparations are applied should not be covered. cream should be applied to a thickness of approximately 16 mm (one-sixteenth inch); the burned area should be covered with cream at all
times. If necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. If possible, the patient should be bathed daily to aid in debridement.
Dressings are usually not required but may be used. Silver sulfadiazine cream should be applied to the burn wound as long as there is a possibility of infection, unless a clinically important adverse reaction occurs. Therapy is usually continued until healing is progressing well or until the site is ready for grafting.
times. If necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. If possible, the patient should be bathed daily to aid in debridement.
Dressings are usually not required but may be used. Silver sulfadiazine cream should be applied to the burn wound as long as there is a possibility of infection, unless a clinically important adverse reaction occurs. Therapy is usually continued until healing is progressing well or until the site is ready for grafting.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
There are 0 contraindications.
There are 4 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Topical Sodium Sulfacetamide/Topical Silver SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2) CLINICAL EFFECTS: Concurrent application of topical sodium sulfacetamide and topical silver preparations may result in decreased clinical effectiveness of the products.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid using topical silver preparations on the same location as topical sodium sulfacetamide products.(1,2) DISCUSSION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2) |
ABENOR, ABENOR HP, APEXOL, APEXOL HP, AVAR, AVAR LS, AVAR-E, BP 10-1, CLEANSING WASH, CLENIA PLUS, DRAXACE, DRAXACEY, DRIXECE, ECEOXIA, KLARON, OXIAICE, PLEXION, PLEXION NS, SODIUM SULFACETAMIDE, SODIUM SULFACETAMIDE-SULFUR, SSS 10-5, SULFACETAMIDE, SULFACETAMIDE SOD MONOHYDRATE, SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM-SULFUR, SULFACLEANSE 8-4, SUMADAN, SUMADAN XLT, SUMAXIN, SUMAXIN CP, SUMAXIN TS, ZMA CLEAR |
| Topical Collagenase; Papain/Topical Heavy Metals SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Heavy metal ions may inactivate collagenase(1) and papain(2-10). CLINICAL EFFECTS: Application of heavy metal ions such as lead, mercury, and silver may inactivate collagenase(1) and papain,(2-8) limiting their effectiveness. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid applying topical products that contain heavy metals such as lead, mercury, or silver to the same wound areas as collagenase(1) and papain.(2-10) DISCUSSION: The enzymatic activity of collagenase is adversely affected by heavy metal ions such as mercury and silver, which are used in some antiseptics.(1) Papain may be inactivated by heavy metal ions such as lead, mercury, and silver.(2-10) |
COLLAGENASE, SANTYL |
| Radioactive Iodide/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(2) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(3) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1) |
ADREVIEW, JEANATOPE, MEGATOPE, SODIUM IODIDE I-123, VOLUMEX |
| Sodium Iodide I 131/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1,2) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1,2) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1,2) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(3) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(4) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1,2) |
HICON, SODIUM IODIDE I-131 |
There are 0 moderate interactions.
The following contraindication information is available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
| Pregnancy |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Porphyria |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Anemia |
| Disease of liver |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Leukopenia |
| Thrombocytopenic disorder |
The following adverse reaction information is available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 10 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Agranulocytosis Aplastic anemia Erythema multiforme Exfoliative dermatitis Hemolytic anemia Interstitial nephritis Leukopenia Stevens-johnson syndrome Thrombocytopenic disorder Toxic epidermal necrolysis |
There are 5 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Pruritus of skin Stinging of skin |
| Rare/Very Rare |
|---|
|
Dyschromia Skin photosensitivity Skin rash |
The following precautions are available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproduction studies in rabbits using silver sulfadiazine 3-10 times the usual human dosage have not revealed evidence of harm to the fetus. There are no adequate and controlled studies to date using silver sulfadiazine in pregnant women, and the drug should be used during pregnancy only when clearly needed. The drug is not recommended for use in pregnant women unless the burned area covers more than 20% of the body surface or the therapeutic benefits to the patient outweigh the possible risks to the fetus. Because sulfonamide therapy has produced kernicterus in neonates, silver sulfadiazine cream is contraindicated in pregnant women approaching or at term.
It is not known whether silver sulfadiazine is distributed into human milk. Because sulfonamides are distributed into milk and sulfonamides may cause kernicterus in infants younger than 2 months of age, silver sulfadiazine should be used with caution in nursing women.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
| Drug Name | Excretion Potential | Effect on Infant | Notes |
|---|---|---|---|
| Povidone Iodine | Excreted.This drug is known to be excreted in human breast milk. | This drug has been shown to have an adverse effect on the nursing infant. | Some absorption with top/vag use;May increase iodine levels in nursing infant |
| Silver Sulfadiazine | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Do not breast feed if infant is hyperbilirubinemic or g6Pd deficient. |
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for RAYASORE KIT (silver sulfadiazine/povidone-iodine/alginate dressing)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool